DexCom (DXCM) Misses Q4 Earnings Estimates
DexCom (DXCM) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.50 per share a year ago.
Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast
Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations
Dexcom stock fell late Thursday after the company missed fourth-quarter profit expectations by a nickel per share. The post Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations appeared first on Investor's Business Daily.
DXCM Q4 Earnings to Reflect Market Expansion & Stelo Impact?
DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, driving momentum and market expansion into 2025.
Countdown to DexCom (DXCM) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Should You Buy DexCom Stock Before Feb. 13?
DexCom (DXCM 1.51%) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels.
Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade
Medical device specialist DexCom (DXCM -0.90%) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to unimpressive financial results, especially in the second and third quarters.
DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?
DexCom Inc. DXCM is off to a strong start in 2025, with its stock rallying 5.7% following the release of its preliminary results for the fourth quarter and fiscal 2024 on Jan. 13, 2025. The company's robust performance has reaffirmed investor confidence, driven by impressive revenue growth and a promising outlook for 2025.
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, with muted enthusiasm from Wall Street today, and a "Hold" rating for me for 2025. I suspect the market overestimated DexCom's mass-market potential, leading to a reality check and a savage bear run on its stock in the past year.
2 Healthcare Stocks to Buy Hand Over Fist in January
Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a single 30-day period.
DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook
DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM continues to raise optimism among investors owing to its strong product portfolio.
